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INTRODUCTION
Community respiratory viruses (CRVs) include the
inﬂuenza viruses, parainﬂuenza virus (PIV), respiratory syn-
cytial virus (RSV), rhinoviruses, and adenoviruses. These
viruses not only cause respiratory tract infections in the
community but also are associated with pneumonia and
increased mortality among recipients of hematopoietic stem
cell transplants (HSCTs). The pattern of CRV infection
among HSCT recipients mirrors that in the surrounding
community, but these highly contagious infections also have
a high potential for nosocomial spread [1-5].
At the Fred Hutchinson Cancer Research Center
(FHCRC), we have studied CRV infections in the HSCT
population since 1988. Epidemiologic data are collected
through active surveillance. Nasopharyngeal wash and throat
swab specimens are obtained from all HSCT recipients
with symptoms of respiratory virus infections, and the spec-
imens are tested for CRVs by the direct ﬂorescent antibody
(DFA) test as well as by shell vial culture and conventional
culture. The same tests are applied to all bronchoalveolar
lavage (BAL) samples, sinus aspirates, lung biopsies, and
autopsy specimens. 
Retrospective analyses of risk factors for RSV [6] and
PIV [7] infections in HSCT recipients at FHCRC have
recently been completed and are summarized here, along
with an overview of uncontrolled treatment trials and infor-
mation on 2 ongoing trials of treatment for RSV infection.
RSV INFECTIONS
Epidemiology
The ﬁrst CRV to be studied systematically at FHCRC
was RSV, which is associated with serious morbidity and
high mortality among HSCT recipients [8,9]. RSV infection
is seasonal, with the majority of infections occurring
between January and April and virtually no infections occur-
ring between August and October. As shown in Figure 1,
serious RSV pneumonia outbreaks occurred at FHCRC in
1990 (31 patients with RSV infection, 18 with RSV pneu-
monia), 1994 (28 patients with RSV infection, 12 with RSV
pneumonia), and 1997 (41 patients with RSV infection,
24 with RSV pneumonia). 
From 1989 to 1999, RSV infection developed in 171 of
3897 HSCT recipients. The overall attack rate was 4.5%,
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but the attack rate among patients who received transplants
during the winter RSV season was approximately 10%. A
total of 103 (60%) patients had upper respiratory tract
infections (URTIs) alone, 54 (32%) had URTIs that pro-
gressed to pneumonia at a median of 7 days after the onset
of upper respiratory tract symptoms, and 14 (8%) had pneu-
monia alone without preceding upper respiratory tract signs
or symptoms. The occurrence of BAL-proven RSV pneu-
monia in the absence of signs attributable to a CRV high-
lights the importance of testing all BAL specimens for the
presence of these viruses.
Risk Factors 
At FHCRC, we recently completed a retrospective
analysis of risk factors for RSV infection and progression to
pneumonia in HSCT recipients from 1989 to 1999 [6]. Our
goals were to identify risk factors for development of RSV
URTI, to identify characteristics that predict progression of
RSV URTI to RSV pneumonia, and to determine the
impact of RSV infection on overall mortality among HSCT
recipients. Surveillance for RSV infection was conducted as
described above. RSV URTI was deﬁned as detectable RSV
in the nasopharynx, throat, or sinuses; RSV pneumonia was
deﬁned as radiographic and clinical evidence of pneumonia
in the presence of RSV in BAL fluid and/or lung tissue
specimens. Between 1994 and 1997, this retrospective analy-
sis included some patients with RSV URTI who had partici-
pated in a pilot study of preemptive treatment with low-dose
aerosolized ribavirin (2 g given once over 2 hours/d). 
In a univariate analysis, male sex was found to increase the
risk of contracting any RSV infection (Table 1). Age, donor
type, use of total body irradiation (TBI), cytomegalovirus
(CMV) serostatus, herpes simplex virus (HSV) serostatus,
underlying disease, source of stem cells, engraftment status,
presence of graft-versus-host disease (GVHD), and year of
HSCT had no impact on RSV infection risk.
Because of the interest in preemptive treatment to pre-
vent progression of RSV URTI to pneumonia, risk factors
for disease progression were analyzed (Table 1). In a multi-
variate analysis, older age was signiﬁcantly associated with
progression to pneumonia, as was the receipt of stem cells
from a mismatched or unrelated donor. Underlying disease,
use of TBI, CMV serostatus, HSV serostatus, preemptive
use of low-dose aerosolized ribavirin (2 g once a day), and
acute GVHD did not signiﬁcantly affect the risk of disease
progression to pneumonia. The use of corticosteroids was
not considered in this model.
Finally, the effect of RSV infection on mortality after
HSCT was determined by multivariate analysis adjusted for
age, sex, underlying disease and disease risk, donor type, use
of TBI, CMV serostatus, HSV serostatus, source of stem
cells, and year of transplant (Table 1). Any RSV infection
acquired after HSCT was found to increase mortality risk
by 60%.
PIV INFECTIONS
Epidemiology
We recently completed and published a comprehensive
analysis of parainfluenza virus (PIV) infections after stem
cell transplantation at our center [7]. Indeed, the most com-
mon CRV infection at FHCRC in the period between 1990
and 1999 was PIV. Except for outbreaks in 1993, 1998, and
1999, PIV occurred at a relatively constant rate. The varia-
tions in PIV incidence throughout the year were much less
pronounced than those for RSV; June, July, and October
were the months of peak PIV incidence. 
From 1990 to 1999, 253 cases of PIV infection occurred
among 3577 HSCT recipients, an attack rate of 7.1%. Of
these cases, 228 (90%) were caused by PIV-3. The clinical
presentation of PIV-3 differed from that of RSV: 87% of
patients had signs and symptoms of URTI alone; 6% had
Figure 1. Respiratory syncytial virus pneumonia outbreaks among HSCT recipients at Fred Hutchinson Cancer Research Center, 1990 to 1999.
Major outbreaks occurred in 1990, 1994, and 1997. 
Table 1. Risk Factors for RSV Infection, Progression to RSV Pneumonia,
and Overall Mortality Among 3897 HSCT Recipients at FHCRC, 1990 to
1999*
Risk Factor Hazard Ratio 95% CI P
For RSV infection
Male sex 1.4 1.04-2.0 .03
For progression to pneumonia
Age (continuous) — — .005
Mismatched/unrelated donor 2.8 1.4-5.7 .006
For impact on mortality
Any RSV infection (time 1.6 1.3-2.0 <.001
dependent)
*Data from [6]. CI indicates conﬁdence interval.
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signs and symptoms of both URTI and lower respiratory
tract infection (LRTI); and 7% had only LRTI signs and
symptoms. Among those who presented with URTI alone,
infections progressed to LRTI in 13%, at a median of 3 days.
There were a total of 55 PIV-3 LRTIs. 
Risk Factors
In a univariate analysis, the use of an unrelated stem cell
donor was found to be the only factor signiﬁcantly associ-
ated with an increased risk of PIV-3 infection (Table 2). Age,
conditioning regimen, CMV serostatus, underlying disease,
engraftment status, and presence of GVHD had no signiﬁ-
cant effect on the incidence of PIV infection.
In a multivariate analysis, the risk of progression of PIV-
3 URTI to pneumonia was found to be increased by the use
of corticosteroids, in a dose-dependent fashion (Table 2);
patients receiving corticosteroids at a dosage of ≥2 mg/kg
per day had a 19.8-fold increase in risk. Patient age, donor
age, donor type, CMV serostatus, underlying disease, use of
TBI, engraftment status, and presence of GVHD had no
significant effect on progression to PIV pneumonia once
corticosteroids were in the model.
The effect of PIV-3 infection on mortality after HSCT
was also analyzed, in a multivariate analysis adjusted for age,
CMV serostatus, donor type, and underlying disease (Table
2). Any PIV-3 infection was associated with a 1.6-fold
increase in mortality risk; a greater increase in mortality risk
was found for patients with PIV-3 LRTI, although patients
with PIV-3 URTI also had a statistically signiﬁcant increase
in the risk for overall mortality. 
A factor contributing to increased mortality among
HSCT recipients with PIV-3 infection may have been the
presence of co-pathogens, which were found in 29 of
55 cases of PIV-3 LRTI. Mortality rates were much higher
among HSCT recipients with a PIV-3 infection and a co-
pathogen than among those without a co-pathogen. The
most common co-pathogen was Aspergillus fumigatus (found
in 13 patients), which causes highly lethal infections. Of
note, in a separate analysis of risk factors for postengraft-
ment aspergillosis among HSCT recipients at our center,
PIV infection was found to be an independent predictor of
late aspergillosis. 
TREATMENT OF RSV INFECTION 
HSCT Recipients With RSV Pneumonia at FHCRC
The mortality rate for RSV pneumonia among HSCT
recipients at FHCRC has declined since 1990. In each of the
3 RSV outbreaks in the past decade, some patients with RSV
pneumonia were treated empirically with aerosolized rib-
avirin (1990 and 1997) or intravenous ribavirin (1994). In
1990, 13 of 18 patients with RSV pneumonia were treated
with aerosolized ribavirin [8]. Most did not receive the full
course of therapy, 6 g of aerosolized ribavirin over 18 hours
in each 24-hour period for 10 days. The mortality rate was
approximately 70% among treated patients; all survivors
were treated for ≥5 days. Mortality was 100% among the
5 untreated patients.
Between November 1993 and May 1994, 10 patients with
RSV pneumonia received intravenous ribavirin (loading dose,
35 mg/kg in 3 divided doses every 8 hours; maintenance dose,
25 mg/kg in 3 divided doses every 8 hours for 6 days) [10].
Two (20%) patients survived, both of whom had few radi-
ographic inﬁltrates and required only minimal supplemental
oxygen. In 2 patients, hemolysis developed that required pre-
mature discontinuation of therapy [10]. In 1997, we thus
returned to the use of aerosolized ribavirin (2 g aerosolized
ribavirin over 2 hours 3 times daily for 10 days) for 24 patients
with BAL-conﬁrmed RSV pneumonia. The mortality rate for
this population was 33% (unpublished data). 
Although a formal statistical analysis has not yet been
completed, several factors may have contributed to the great
difference in RSV mortality rates between those treated
with aerosolized ribavirin during the 1990 RSV outbreak
and those treated during the 1997 RSV outbreak. The most
important of these factors was a decrease in the time to
diagnosis. In 1990, diagnosis was generally delayed in
patients with signs and symptoms of pneumonitis. Nasopha-
ryngeal specimens were obtained after several days, and
BAL ﬂuid was often obtained only if URTI specimens were
negative for RSV. By 1997, however, the approach to diag-
nosis was more aggressive, with BAL specimens being
obtained and tested early in the course of illness. At the start
of aerosolized ribavirin therapy, most patients in the 1990
cohort required high-dose supplemental oxygen or mechan-
ical ventilation, whereas few patients in the 1997 cohort
required any supplemental oxygen. This fact suggests that
aerosolized ribavirin may be most effective when used early
in the course of RSV pneumonia, which mandates rapid
diagnostic algorithms.
Another factor that could have contributed to the widely
different mortality rates was the addition of intravenous
immunoglobulin (IVIG) to aerosolized ribavirin for 19 of
24 patients treated in 1997. In a univariate analysis, how-
ever, survival was similar among patients who received con-
comitant pooled IVIG and those who did not. 
Ongoing Controlled Clinical Trials
In recent years, most transplantation centers have
reported lower RSV mortality among HSCT recipients, but
in the absence of data from controlled clinical trials, it has
Table 2. Risk Factors for PIV Infection, Progression to Pneumonia, and
Overall Mortality Among 3577 HSCT Recipients at FHCRC, 1991 to
1999*
Risk Factor Hazard Ratio 95% CI P
For PIV acquisition
Unrelated donor 1.6 1.1-2.3 .02
For progression to pneumonia 
No corticosteroids 1.0
<1 mg/kg per d of corticosteroids 2.5 0.7-8.3 .14
1 to <2 mg/kg per d of 6.4 2.1-19.0 .0009
corticosteroids
≥2 mg/kg per d of corticosteroids 19.8 5.5-68.3 <.0001
For impact on mortality
No PIV infection 1.0
Any PIV infection 1.6 1.3-1.9 <.0001
PIV URTI 1.3 1.1-1.6 .02
PIV LRTI 3.4 2.4-4.7 <.0001
*Data from [7].
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been difficult to evaluate the benefits of treatment or to
compare regimens. Two controlled clinical trials that may
provide such data are currently in progress. 
Aerosolized Ribavirin Plus Palivizumab. The efficacy of
aerosolized ribavirin plus palivizumab (a monoclonal RSV
antibody preparation) is currently being evaluated in a com-
parative randomized controlled clinical trial conducted by
the Collaborative Antiviral Study Group (CASG) and the
National Institute of Allergy and Infectious Diseases
(NIAID). In this study, HSCT recipients with RSV LRTI
are treated with aerosolized ribavirin with or without
palivizumab. The primary end point is all-cause mortality at
28 days after randomization; secondary end points include
days of hospitalization, days in the intensive care unit, days
of mechanical ventilation, and safety outcomes.
Aerosolized Ribavirin to Prevent Progression to Pneumonia.
Progression to pneumonia occurs in approximately 50% of
HSCT recipients with RSV URTI [1,4,8]. Once estab-
lished, RSV pneumonia leads to death in 45% to 80% of
these patients.
The treatment of RSV URTI with aerosolized ribavirin
has been examined in several pilot studies, including 1 at
FHCRC (unpublished observations) and 1 at M.D. Ander-
son Cancer Center (MDACC) [7]. In the FHCRC study, as
noted above, aerosolized ribavirin (2 g once daily for 5-7 days)
had no effect on progression to pneumonia. In the MDACC
study, 14 patients were treated with aerosolized ribavirin
(6 g daily)—in either a conventional regimen (20 mg/mL
3 times daily over 18 hours/d) or a high-dose, short-duration
regimen (60 mg/mL for 2 hours 3 times daily)—plus IVIG
(500 mg/kg every other day) [7]. The URTI resolved in
10 (71%) patients; pneumonia developed in the other
4 patients (during preengraftment in 3), 2 of whom died
[11]. However, comparison with historical controls and for-
mal statistical analysis were not performed in this study. 
The prevention of progression of RSV URTI to pneu-
monia in HSCT recipients is being addressed in a second
ongoing multicenter CASG/NIAID study (CASG-202). In
this phase III study, the safety and efficacy of aerosolized
ribavirin are being evaluated in HSCT recipients with RSV
URTI infection and without signs of LRTI. The study
patients are randomized to treatment with aerosolized rib-
avirin (2 g 3 times daily for 10 days) or to placebo and close
daily observation. The primary end point of the study is
progression to pneumonia, which is assessed by an evaluator
blinded to the patients’ treatment assignments. Secondary
end points are RSV pneumonia, conﬁrmed by the results of
culture or a DFA test, and safety evaluations. 
To be eligible for study entry, HSCT patients must have
signs and symptoms of URTI and RSV infection conﬁrmed
by DFA or shell vial tests of nasopharyngeal wash speci-
mens. Patients must have undergone HSCT ≤90 days previ-
ously, or ≤180 days previously if the stem cell donor was
unrelated or if stem cells came from cord blood. HSCT
recipients who underwent transplant from other sources
≥90 days previously but who have GVHD requiring systemic
corticosteroids in a daily dose of >1 mg/kg are also eligible. 
To detect a reduction in risk of progression to pneumo-
nia from 50% (background) to 20% with 80% power at the
5% signiﬁcance level, a sample size of 90 patients is required.
Patients are stratiﬁed by engraftment status and transplant
type (mismatched and unrelated donors versus other types).
TREATMENT OF PIV INFECTION
PIV-3 infections are relatively common among HSCT
recipients and are an independent risk factor for increased
mortality. PIV infections appear to be less responsive to
aerosolized ribavirin than RSV infections. Once PIV-3 pneu-
monia was established, the use of ribavirin with or without
IVIG at our center had no effect on 30-day mortality rates,
even after stratiﬁcation for co-pathogens (Figure 2) [7]. Over-
all mortality was lower among patients with PIV-3 LRTI who
had no co-pathogen. Because progression to pneumonia is
common among those with ongoing treatment with corticos-
teroids, one should consider decreasing immunosuppression
if at all possible for those with PIV URTIs.
PREVENTION OF CRV INFECTIONS
In the absence of treatments with proven efficacy
against CRV infections in HSCT recipients, prevention of
Figure 2. Thirty-day mortality rates for 55 HSCT recipients at Fred Hutchinson Cancer Research Center with PIV-3 LRTI with or without a
co-pathogen after treatment with aerosolized ribavirin plus intravenous immunoglobulin (IVIG), treatment with aerosolized ribavirin, or no treatment.
(From Nichols WG, Corey L, Gooley T, Davis C, Boeckh M. Parainﬂuenza virus infections after hematopoietic stem cell transplantation: risk factors,
response to antiviral therapy, and effect on transplant outcome. Blood. 2001;98:573-578. Copyright American Society of Hematology, used by permission.)
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such infections is the ﬁrst line of defense. Strict enforcement
of hand washing is the mainstay of protection, while the use
of masks to prevent droplet transmission is more controver-
sial. Standard infection-control procedures at FHCRC have
included strict respiratory isolation for patients with symp-
toms of URTI until cultures are negative for CRVs, but this
policy alone did not prevent the 1997 RSV outbreak. Subse-
quent investigation of this outbreak indicated that a single
infected healthcare worker was probably the source of infec-
tion of 10 patients within a 10-day period. We therefore
instituted a sign-in policy during winter respiratory virus
seasons. Before entering the transplantation ward, staff and
visitors must state that they are free of all URTI symptoms.
Staff members with any symptoms must remain absent from
work until the symptoms have resolved. Because the cost of
staffing during the winter RSV season is high, this policy
requires a major institutional commitment. 
This policy may have reduced the incidence of RSV
infection, but the largest outbreak of PIV-3 infection
occurred in 1999, after the policy had been in effect for sev-
eral years. The incidence of PIV-3 infection does not have
great seasonal variations, so the winter sign-in policy did not
affect the incidence of infections during the spring and sum-
mer. However, the PIV-3 outbreaks in 1998 and 1999
occurred during the winter season, when the sign-in policy
was in effect, and without a great increase in PIV infections
in the surrounding community. The outbreak continued
over a 6-month period, and the incidence of PIV-3 was sim-
ilar in inpatient and outpatient units. Contrary to expecta-
tions, 10 of 19 isolates obtained from patients at different
locations and at different times had identical sequences
(unpublished data). These ﬁndings suggest that PIV infec-
tions in immunocompetent persons (such as healthcare
workers) may result in viral shedding, even while the host is
asymptomatic. Prevention of PIV infections, even with the
use of strict infection-control strategies, may be difﬁcult. 
CONCLUSIONS
CRV infections remain significant causes of morbidity
and mortality among HSCT recipients. Both RSV and PIV
infections may progress from URTI to pneumonia, and mor-
tality due to pneumonia is high. Current treatment options
for PIV infections are limited, while those for RSV are more
promising. Ongoing clinical trials should provide new data
on optimal therapy for RSV infection and prevention of the
progression of RSV URTI to pneumonia. Vaccines for RSV
and PIV that could be used among healthcare workers and
caregivers are badly needed to limit nosocomial spread of
these viruses, as are new medications that are active against
PIV. For now, infection control must be accorded high prior-
ity in the care of the immunocompromised HSCT recipient.
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